Description
Nab-sirolimus is an albumin-bound nanoparticle formulation of sirolimus (rapamycin), an mTOR inhibitor being investigated for various cancer types. It is designed to improve the delivery and therapeutic index of sirolimus by utilizing albumin nanoparticle technology similar to nab-paclitaxel.
Mechanism of Action
It inhibits the mechanistic target of rapamycin (mTOR) pathway, which regulates cell growth, proliferation, and survival in cancer cells.
Side Effects
Fatigue
Nausea
Decreased appetite
Immunosuppression
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT03439462
Phase 1
Archived
Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer
United States